Clinical and Experimental Allergy最新文献

{"title":"Psychometric Validation of the Traditional Chinese Chronic Urticaria Quality of Life Questionnaire.","authors":"Hugo W F Mak, Elaine Lee, Jane C Y Wong, Philip H Li","doi":"10.1111/cea.14586","DOIUrl":"https://doi.org/10.1111/cea.14586","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eosinophil-Derived Neurotoxin Determinants and Reference Values in a Swedish Middle-Aged General Population.","authors":"Suneela Zaigham, Nils Oskar Jõgi, Robert Movérare, Anders Sjölander, Niclas Rydell, Magnus Molin, Christer Janson, Andrei Malinovschi","doi":"10.1111/cea.14579","DOIUrl":"https://doi.org/10.1111/cea.14579","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathomechanism of Adverse Reactions to Biological Treatment of Inflammatory Skin Conditions.","authors":"Lichen Li, Dean J Naisbitt, Yonghu Sun, Furen Zhang","doi":"10.1111/cea.14583","DOIUrl":"https://doi.org/10.1111/cea.14583","url":null,"abstract":"<p><p>Biological agents are widely used across medicine, including for immune-mediated skin conditions such as psoriasis and atopic dermatitis. When used to treat a relevant pathological process, they demonstrate impressive efficacy and credible safety, helping to achieve remission and improved function and quality of life. However, with their expanded use, awareness and understanding of adverse reactions to biologicals have also increased. Herein, we discuss the pathomechanism of adverse reactions to biological agents used to treat skin conditions and apply these to Pichler's classification system. This classification differentiates five distinct types, namely overstimulation (type α), hypersensitivity or immunogenicity (β), immunodeviation (γ), cross-reactivity (δ) and nonimmunologic adverse reactions (ε). This classification covers most types of adverse reactions associated with use of biological agents and could be used to better understand the reaction pathogenesis and manage the clinical features of biological adverse effects.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Noninvasive Nasal Secretion Sampling for Assessing Inflammatory Phenotype of Adult Allergic Rhinitis Patients.","authors":"Liyue Li, Ziyi Long, Qianxue Hu, Pei Gao, Yue Zhou, Shan Chen, Tao Zhou, Liuqing Zhou, Qing Cheng, Hongjun Xiao, Jianjun Chen","doi":"10.1111/cea.14580","DOIUrl":"https://doi.org/10.1111/cea.14580","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole Blood Transcriptomics Identifies Differences in Innate Immune Pathway Expression in Infants at Risk for Peanut Allergy.","authors":"Abigail Lang, Samantha Gadd, Lauren Gunderman, Elizabeth Lippner, Ashley Devonshire, Matthew J Schipma, Sergejs Berdnikovs, Rajesh Kumar","doi":"10.1111/cea.14587","DOIUrl":"https://doi.org/10.1111/cea.14587","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutrition Industry Sponsorship of Healthcare Professional Associations","authors":"Robert J. Boyle,&nbsp;Victoria L. Sibson,&nbsp;Christoffer van Tulleken","doi":"10.1111/cea.14581","DOIUrl":"https://doi.org/10.1111/cea.14581","url":null,"abstract":"&lt;p&gt;Last month, the World Health Organisation (WHO) published new resources to support Healthcare Professional Associations (HCPA) wishing to avoid conflicts of interest in relation to nutrition companies marketing foods for infants and young children. The new WHO resources include a model policy, suggestions for alternative funding sources and case studies of good practice [&lt;span&gt;1&lt;/span&gt;]. The case studies include the Indian Academy of Paediatrics and examples from Africa, which are especially important given the harms associated with formula marketing in these regions [&lt;span&gt;2&lt;/span&gt;]. The new resources underscore a long-standing WHO recommendation, made more explicit since 2016—that HCPA (and health workers) should not accept funding from companies that market foods for infants and young children, for either the general running of the HCPA or for supporting HCPA educational or scientific meetings such as an annual congress [&lt;span&gt;3&lt;/span&gt;]. The scope of ‘foods’ that relevant companies might market is quite broad, including formula, ‘growing up’ drinks, specialised low-allergy formula, non-liquid foods and even bottles and teats sold for formula feeding. The scope of ‘infants and young children’ is from birth through to age 36 months, the period of time covered by the International Code of Marketing of Breastmilk Substitutes.&lt;/p&gt;&lt;p&gt;This WHO recommendation has met with significant resistance from HCPAs, including some allergy HCPAs [&lt;span&gt;4&lt;/span&gt;]. Two key reasons cited for continuing to accept nutrition industry funding are access to scientific information about nutrition products, and difficulty funding educational and scientific activities without nutrition industry support [&lt;span&gt;5&lt;/span&gt;]. Access to scientific information about nutrition products does not require a financial relationship, since companies already provide product information in the public domain and on request, without any exchange of funding. Finding alternative resources for educational and scientific activities is more challenging. So these new WHO resources aim to support HCPAs to address this challenge.&lt;/p&gt;&lt;p&gt;This month, the British Society for Allergy and Clinical Immunology (BSACI) hosted its first annual conference without sponsorship from any company that markets foods for infants and young children. It is 5 years since the society's announcement that it will no longer accept funding from commercial formula milk companies for its conference and educational activities. Culture change takes time, and reducing income sources is not something which organisations find easy. This is recognised by the WHO, hence the inclusion of case studies to help HCPAs understand that they are not alone in finding this difficult, and a journey is often required to transition away from nutrition industry funding. There are a number of other allergy societies which take a similar approach to BSACI of avoiding formula industry sponsorship. However, these are dwarfed by the major allergy HC","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 10","pages":"720-722"},"PeriodicalIF":6.3,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14581","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142449087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cochrane Corner: Pharmacological Treatment of Gastro-Oesophageal Reflux in Children.","authors":"Aahil Damani, Nabeela Bhaloo","doi":"10.1111/cea.14577","DOIUrl":"https://doi.org/10.1111/cea.14577","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With Mepolizumab.","authors":"Danilo Di Bona, Massimo Bilancia, Claudia Crimi, Michelina Daddato, Alida Benfante, Maria Filomena Caiaffa, Cecilia Calabrese, Raffaele Campisi, Santi Nolasco, Giovanna Elisiana Carpagnano, Maria D'Amato, Corrado Pelaia, Girolamo Pelaia, Angelantonio Maglio, Nicola Scichilone, Giulia Scioscia, Giuseppe Spadaro, Massimo Triggiani, Isabella Carrieri, Giuseppe Valenti, Alessandro Vatrella, Luigi Macchia, Nunzio Crimi","doi":"10.1111/cea.14584","DOIUrl":"https://doi.org/10.1111/cea.14584","url":null,"abstract":"<p><p>This study identifies two distinct subgroups of patients with severe eosinophilic asthma who respond differently to mepolizumab. Cluster analysis reveals that patients with a family history of asthma, positive skin prick tests and higher baseline lung function have better treatment outcomes, highlighting the value of personalised treatment strategies.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anaphylaxis Management in Paediatric Patients Undergoing Milk Oral Immunotherapy.","authors":"Dimitry Buyansky, Roy Khalaf, Sofianne Gabrielli, Julia Upton, Eyal Grunebaum, Edmond S Chan, Ingrid Baerg, Liane Beaudette, Danbing Ke, Bruce Mazer, Christine McCusker, Duncan Lejtenyi, Moshe Ben-Shoshan","doi":"10.1111/cea.14582","DOIUrl":"https://doi.org/10.1111/cea.14582","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adrenaline Auto-Injectors for Preventing Fatal Anaphylaxis.","authors":"Marcus Sim, Vibha Sharma, Karen Li, Mary H Gowland, Tomaz Garcez, Cassandra Shilladay, Richard Pumphrey, Nandinee Patel, Paul J Turner, Robert J Boyle","doi":"10.1111/cea.14565","DOIUrl":"https://doi.org/10.1111/cea.14565","url":null,"abstract":"<p><p>Anaphylaxis affects up to 5% of people during their lifetime. Although anaphylaxis usually resolves without long-term physical consequences, it can result in anxiety and quality of life impairment. Rarely and unpredictably, community anaphylaxis can cause rapid physiological decompensation and death. Adrenaline (epinephrine) is the cornerstone of anaphylaxis treatment, and provision of adrenaline autoinjectors (AAI) has become a standard of care for people at risk of anaphylaxis in the community. In this article, we explore the effectiveness of AAIs for preventing fatal outcomes in anaphylaxis, using information drawn from animal and human in vivo studies and epidemiology. We find that data support the effectiveness of intravenous adrenaline infusions for reversing physiological features of anaphylaxis, typically at doses from 0.05 to 0.5 μg/kg/min for 1-2 h, or ~ 10 μg/kg total dose. Intramuscular injection of doses approximating 10 μg/kg in humans can result in similar peak plasma adrenaline levels to intravenous infusions, at 100-500 pg/mL. However, these levels are typically short-lived following intramuscular adrenaline, and pharmacokinetic and pharmacodynamic outcomes can be unpredictable. Epidemiological data do not support an association between increasing AAI prescriptions and reduced fatal anaphylaxis, although carriage and activation rates remain low. Taken together, these data suggest that current AAIs have little impact on rates of fatal anaphylaxis, perhaps due to a lack of sustained and sufficient plasma adrenaline concentration. Effects of AAI prescription on quality of life may be variable. There is a need to consider alternatives, which can safely deliver a sustained adrenaline infusion via an appropriate route.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}